Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK)
HKD 13.98
(1.16%)
HKD 13.98
(1.16%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.3 Billion CNY | -60.13% |
| 2022 | 8.29 Billion CNY | 31.41% |
| 2021 | 6.31 Billion CNY | 33.73% |
| 2020 | 4.72 Billion CNY | -26.38% |
| 2019 | 6.41 Billion CNY | 81.39% |
| 2018 | 3.53 Billion CNY | -13.24% |
| 2017 | 4.07 Billion CNY | 19.87% |
| 2016 | 3.39 Billion CNY | 3.1% |
| 2015 | 3.29 Billion CNY | 37.71% |
| 2014 | 2.39 Billion CNY | -15.06% |
| 2013 | 2.81 Billion CNY | 38.45% |
| 2012 | 2.03 Billion CNY | 28.82% |
| 2011 | 1.58 Billion CNY | 38.59% |
| 2010 | 1.14 Billion CNY | -64.49% |
| 2009 | 3.21 Billion CNY | 297.75% |
| 2008 | 807.55 Million CNY | 9.62% |
| 2007 | 736.68 Million CNY | 112.22% |
| 2006 | 347.13 Million CNY | 48.06% |
| 2005 | 234.45 Million CNY | -21.37% |
| 2004 | 298.18 Million CNY | -9.48% |
| 2003 | 329.41 Million CNY | 95.5% |
| 2002 | 168.49 Million CNY | 16.96% |
| 2001 | 144.06 Million CNY | 1.53% |
| 2000 | 141.89 Million CNY | 33.45% |
| 1999 | 106.33 Million CNY | 37.49% |
| 1998 | 77.33 Million CNY | 56.97% |
| 1997 | 49.27 Million CNY | 402.53% |
| 1996 | 9.8 Million CNY | 12.79% |
| 1995 | 8.69 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 907.92 Million CNY | -11.11% |
| 2024 Q3 | 1.17 Billion CNY | 29.78% |
| 2024 Q1 | 1.02 Billion CNY | 3044.27% |
| 2023 FY | 3.3 Billion CNY | -60.13% |
| 2023 Q1 | 1.42 Billion CNY | 34.11% |
| 2023 Q2 | 1.25 Billion CNY | -12.03% |
| 2023 Q3 | 659.58 Million CNY | -47.46% |
| 2023 Q4 | -34.68 Million CNY | -105.26% |
| 2022 Q4 | 1.06 Billion CNY | -27.44% |
| 2022 Q1 | 2.44 Billion CNY | 51.24% |
| 2022 Q2 | 1.65 Billion CNY | -32.39% |
| 2022 Q3 | 1.46 Billion CNY | -11.16% |
| 2022 FY | 8.29 Billion CNY | 31.41% |
| 2021 Q1 | 1.15 Billion CNY | -12.9% |
| 2021 Q2 | 2.16 Billion CNY | 87.01% |
| 2021 Q3 | 1.37 Billion CNY | -36.75% |
| 2021 Q4 | 1.61 Billion CNY | 17.72% |
| 2021 FY | 6.31 Billion CNY | 33.73% |
| 2020 Q3 | 1.06 Billion CNY | -30.31% |
| 2020 Q2 | 1.53 Billion CNY | 94.08% |
| 2020 Q4 | 1.33 Billion CNY | 24.65% |
| 2020 Q1 | 789.58 Million CNY | -49.46% |
| 2020 FY | 4.72 Billion CNY | -26.38% |
| 2019 FY | 6.41 Billion CNY | 81.39% |
| 2019 Q3 | 713.74 Million CNY | -41.82% |
| 2019 Q2 | 1.22 Billion CNY | 23.8% |
| 2019 Q4 | 1.56 Billion CNY | 118.89% |
| 2019 Q1 | 990.83 Million CNY | 31.17% |
| 2018 Q2 | 1.07 Billion CNY | 10.48% |
| 2018 Q4 | 755.37 Million CNY | 1.86% |
| 2018 FY | 3.53 Billion CNY | -13.24% |
| 2018 Q1 | 968.56 Million CNY | -1.08% |
| 2018 Q3 | 741.57 Million CNY | -30.7% |
| 2017 Q4 | 979.16 Million CNY | 6.33% |
| 2017 Q3 | 920.84 Million CNY | -25.43% |
| 2017 Q1 | 940 Million CNY | 33.33% |
| 2017 FY | 4.07 Billion CNY | 19.87% |
| 2017 Q2 | 1.23 Billion CNY | 31.37% |
| 2016 Q2 | 1.02 Billion CNY | 24.1% |
| 2016 FY | 3.39 Billion CNY | 3.1% |
| 2016 Q4 | 705 Million CNY | -16.6% |
| 2016 Q3 | 845.38 Million CNY | -17.44% |
| 2016 Q1 | 825.08 Million CNY | 6.09% |
| 2015 FY | 3.29 Billion CNY | 37.71% |
| 2015 Q4 | 777.73 Million CNY | 6.34% |
| 2015 Q3 | 731.4 Million CNY | -32.54% |
| 2015 Q2 | 1.08 Billion CNY | 54.02% |
| 2015 Q1 | 703.88 Million CNY | 124.65% |
| 2014 FY | 2.39 Billion CNY | -15.06% |
| 2014 Q4 | 313.32 Million CNY | -57.03% |
| 2014 Q3 | 729.13 Million CNY | -7.74% |
| 2014 Q2 | 790.31 Million CNY | 46.13% |
| 2014 Q1 | 540.84 Million CNY | -43.07% |
| 2013 Q2 | 967.49 Million CNY | 121.55% |
| 2013 FY | 2.81 Billion CNY | 38.45% |
| 2013 Q1 | 436.7 Million CNY | -19.8% |
| 2013 Q3 | 464.65 Million CNY | -51.97% |
| 2013 Q4 | 949.98 Million CNY | 104.45% |
| 2012 Q1 | 521.86 Million CNY | 176.94% |
| 2012 Q2 | 447.52 Million CNY | -14.25% |
| 2012 Q4 | 544.54 Million CNY | 4.31% |
| 2012 FY | 2.03 Billion CNY | 28.82% |
| 2012 Q3 | 522.05 Million CNY | 16.66% |
| 2011 Q3 | 264.9 Million CNY | -67.16% |
| 2011 Q1 | 320.51 Million CNY | 111.67% |
| 2011 Q2 | 806.64 Million CNY | 151.67% |
| 2011 FY | 1.58 Billion CNY | 38.59% |
| 2011 Q4 | 188.44 Million CNY | -28.86% |
| 2010 FY | 1.14 Billion CNY | -64.49% |
| 2010 Q1 | 473.51 Million CNY | 31.06% |
| 2010 Q3 | 215.81 Million CNY | -27.99% |
| 2010 Q2 | 299.7 Million CNY | -36.71% |
| 2010 Q4 | 151.42 Million CNY | -29.84% |
| 2009 Q2 | 198 Million CNY | 12.56% |
| 2009 Q4 | 361.31 Million CNY | -85.41% |
| 2009 Q3 | 2.47 Billion CNY | 1150.89% |
| 2009 Q1 | 175.9 Million CNY | 168.43% |
| 2009 FY | 3.21 Billion CNY | 297.75% |
| 2008 Q4 | 65.53 Million CNY | -46.21% |
| 2008 Q3 | 121.81 Million CNY | -69.21% |
| 2008 Q2 | 395.6 Million CNY | 76.14% |
| 2008 Q1 | 224.6 Million CNY | -44.38% |
| 2008 FY | 807.55 Million CNY | 9.62% |
| 2007 Q2 | 158.21 Million CNY | 72.73% |
| 2007 FY | 736.68 Million CNY | 112.22% |
| 2007 Q4 | 403.84 Million CNY | 386.32% |
| 2007 Q1 | 91.59 Million CNY | -22.7% |
| 2007 Q3 | 83.03 Million CNY | -47.51% |
| 2006 Q1 | 80.85 Million CNY | 504.14% |
| 2006 Q2 | 84.37 Million CNY | 4.35% |
| 2006 Q3 | 63.41 Million CNY | -24.84% |
| 2006 Q4 | 118.49 Million CNY | 86.86% |
| 2006 FY | 347.13 Million CNY | 48.06% |
| 2005 Q3 | 84.78 Million CNY | -15.99% |
| 2005 Q4 | -20 Million CNY | -123.6% |
| 2005 Q1 | 68.75 Million CNY | 38.54% |
| 2005 FY | 234.45 Million CNY | -21.37% |
| 2005 Q2 | 100.91 Million CNY | 46.77% |
| 2004 FY | 298.18 Million CNY | -9.48% |
| 2004 Q4 | 49.63 Million CNY | -34.6% |
| 2004 Q1 | 85.01 Million CNY | 319.15% |
| 2004 Q2 | 87.65 Million CNY | 3.1% |
| 2004 Q3 | 75.89 Million CNY | -13.42% |
| 2003 Q4 | 20.28 Million CNY | -55.89% |
| 2003 Q3 | 45.98 Million CNY | -79.22% |
| 2003 Q2 | 221.25 Million CNY | 428.15% |
| 2003 Q1 | 41.89 Million CNY | -12.19% |
| 2003 FY | 329.41 Million CNY | 95.5% |
| 2002 Q3 | 37.11 Million CNY | -24.59% |
| 2002 Q2 | 49.2 Million CNY | 42.75% |
| 2002 Q1 | 34.47 Million CNY | 0.0% |
| 2002 Q4 | 47.7 Million CNY | 28.55% |
| 2002 FY | 168.49 Million CNY | 16.96% |
| 2001 FY | 144.06 Million CNY | 1.53% |
| 2000 FY | 141.89 Million CNY | 33.45% |
| 1999 FY | 106.33 Million CNY | 37.49% |
| 1998 FY | 77.33 Million CNY | 56.97% |
| 1997 FY | 49.27 Million CNY | 402.53% |
| 1996 FY | 9.8 Million CNY | 12.79% |
| 1995 FY | 8.69 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | -2212.749% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | -24.184% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 40623.253% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | -7990.773% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 6438.286% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -9076.816% |
| Essex Bio-Technology Limited | 310.32 Million HKD | -965.804% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 5107.885% |
| SSY Group Limited | 1.63 Billion HKD | -101.813% |
| JBM (Healthcare) Limited | 174.2 Million HKD | -1798.63% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | -892.87% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 72.771% |